GE invests in cardiovascular IVD with CardioDx alliance
This article was originally published in Clinica
GE Healthcare has invested $5m CardioDx, a privately-held company specialising in cardiovascular genomic diagnostics. The move is consistent with the company's strategy to expand out of in vivo and into in vitro diagnostics. The news, announced today, also marks the first investment for GE's $250m Healthymagination fund, which was launched last year as part of a $6bn initiative to improve and increase healthcare access.